Survival with first-line bosentan in patients with primary pulmonary hypertension.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionEndothelin receptor antagonists for pulmonary arterial hypertensionTreatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertensionSelective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseCold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertensionThe limits of oral therapy in pulmonary arterial hypertension managementInhalation of Stachybotrys chartarum causes pulmonary arterial hypertension in miceEarly treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured ratsSystematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.Detection of elevated right ventricular extracellular volume in pulmonary hypertension using Accelerated and Navigator-Gated Look-Locker Imaging for Cardiac T1 Estimation (ANGIE) cardiovascular magnetic resonance.Right ventricular mechanics in hypertrophic cardiomyopathy using feature tracking.Pulmonary hypertension: diagnosis and managementHemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthaseCirculatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension.Transition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension: a 5-year follow-up.The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesUpdate on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertensionSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updatesLong-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settingsInhaled treprostinil and pulmonary arterial hypertension.Integrated care and optimal management of pulmonary arterial hypertensionInterleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollutionInvestigating cardiac MRI based right ventricular contractility as a novel non-invasive metric of pulmonary arterial pressure.Prostacyclin: an inflammatory paradox.Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertensionOverview of current therapeutic approaches for pulmonary hypertension.Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolPulmonary arterial hypertension: advances in pathophysiology and management.Response to bosentan in children with pulmonary hypertension.Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclinLong term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effectRight Heart Failure during Veno-Venous Extracorporeal Membrane Oxygenation for H1N1 Induced Acute Respiratory Distress Syndrome: Case Report and Literature Review.A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence.
P2860
Q24200714-67A46595-72C2-4287-B419-CF269FFBF4D9Q24240009-511F7074-72DB-412D-B894-3C6DB24ACE8BQ24598400-6E6B3CE9-B055-43EC-A1C0-67A8F4AAB15DQ24681558-AB5A6D5D-01E5-4DC3-9E44-19359F77A039Q24816970-DAC7B744-CF9B-4BA6-9044-DE81995DD6E5Q26773209-F4FF9A87-0D99-4B08-B503-54247B4AD51BQ28385412-15D2CDED-3245-47BB-BE88-1C9C7D5C8FC7Q28730633-D47F82CF-33DE-4417-8D4E-B0DB3899B77FQ30251818-ACB0A035-EBE6-474C-9A62-7D96134F59F9Q30277881-11904FEB-E784-44B2-8983-DF02BEC4C92CQ30441067-3451E976-416E-4E29-81DC-D47C075AF9EDQ33157071-6BBB58F1-89B5-4160-BF95-5FC4491D5DEDQ33532813-C152C328-043D-4CD4-9F60-FF5D8B48D777Q33645081-991BF8B4-3782-4119-BDF3-1A177415D639Q33782838-99F804A9-DDB4-47F5-A885-F926B8C41281Q33788510-A21BAA52-646B-4F7D-BD0A-88F39513E125Q33806206-F951B73F-1A52-4BF5-A4DC-5F3189995C11Q33844740-433968B3-052E-4F65-B012-D1D3ADF7710DQ33849207-64207BA9-E6D3-4DB5-96C0-F2A7E82613F6Q33892575-D6C82EEA-4A5A-40C0-B50B-3BC2A58F2A7DQ33965859-1F648D38-B733-4F68-8AAE-D66F227C5D91Q33965898-E75E7486-96A9-4252-8E68-7B55187965F3Q33965904-5B4D474C-C84D-424D-A881-FE0041CED760Q34254924-1BDBB60C-7A9B-4028-BA52-C3A05B9A504AQ34417507-DBDE0B67-3194-4156-9C9D-7EEF68C28D4CQ34417785-CC385D63-27D9-468A-B5C0-B19782619126Q34782588-F8DADBA2-EBDE-47C7-8680-B4B214413862Q34849991-406C893A-9698-428B-AC34-A8D215AFE6FBQ35025863-7D90AABA-ECFE-4DAE-97B8-70BD867C2F19Q35172737-09A141CD-25CA-451C-8AA6-9C49D100191CQ35412362-78B81F92-DB3C-4BB8-842A-D9F8BD97C50AQ35537385-E76E90C5-A278-4314-A16F-D12D14FCD5F3Q35732584-8BBB3BD7-C2B7-4E35-90B0-511658CDBA32Q35771679-BC6D59CB-5828-4851-AFF3-06005ED8B26BQ35792872-E47A0CF4-0D37-4CF9-BCF1-8F597D5CC441Q35898607-688178D5-E306-4C10-8DAC-BB55569CF2E4Q35956167-49088B35-9E30-435D-A669-91197AF88EBCQ35969128-493D5F1B-3830-4CF1-ABB4-2B3D8B5B4C66Q36013108-53C6787F-99F8-45E5-AF0E-BF5F7325B584Q36192759-A063703B-F92A-47FD-9937-1FEB9B53B816
P2860
Survival with first-line bosentan in patients with primary pulmonary hypertension.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@ast
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@en
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@nl
type
label
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@ast
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@en
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@nl
prefLabel
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@ast
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@en
Survival with first-line bosentan in patients with primary pulmonary hypertension.
@nl
P2093
P1476
Survival with first-line bosentan in patients with primary pulmonary hypertension
@en
P2093
D B Badesch
G Simonneau
M Rainisio
V V McLaughlin
P304
P356
10.1183/09031936.05.00054804
P577
2005-02-01T00:00:00Z